Integra is in an operational repair phase: it is trying to restore product availability, relaunch key tissue-reconstruction products, and rebuild commercial execution after earlier manufacturing and supply problems. Its portfolio is weighted toward neurosurgery and regenerative medicine, with management previously highlighting improving supply reliability and the planned SurgiMend relaunch.
The flooding is now a multi-quarter earnings problem, not just a third-quarter interruption. Integra says the Cincinnati disruption reduced third-quarter revenue by about $7 million and expects another $15 million to $20 million hit in the fourth quarter, with full manufacturing recovery only in the second quarter of 2027. 〔0〕
The full-year outlook was cut materially. Revenue guidance fell to $1.634 billion–$1.654 billion from $1.654 billion–$1.695 billion, while adjusted EPS guidance fell to $2.30–$2.40 from $2.40–$2.50. This is the clearest signal in the filing: recovery timing and lost production are worse than the company assumed in July, even though management says the broader business is improving.
| Metric | Preliminary Q3 2026 | Prior company outlook / comparison | Market reference |
|---|---|---|---|
| Revenue | $410M–$412M | $410M–$425M Q3 outlook | ~$424.6M consensus |
| Adjusted EPS | $0.55–$0.59 | $0.53–$0.61 Q3 outlook | ~$0.57 consensus |
| FY2026 revenue | $1.634B–$1.654B | $1.654B–$1.695B prior guidance | — |
| FY2026 adjusted EPS | $2.30–$2.40 | $2.40–$2.50 prior guidance | — |
| Q3 operating cash flow | Greater than $85M | — | — |
| FY2026 operating cash flow | $190M–$200M | — | — |
Q3 is weaker mainly on revenue, while EPS is roughly in line. The preliminary revenue range is below the published consensus of approximately $424.6 million, while the $0.55–$0.59 adjusted EPS range brackets the roughly $0.57 consensus. The filing therefore reads less like a clean quarterly miss than a negative reset to the recovery path.
Cash generation is the main offset, but it does not undo the operational setback. Integra expects more than $85 million of third-quarter operating cash flow and $190 million–$200 million for the year, supporting its deleveraging and recovery efforts. The company also says it is using inventory and alternate suppliers to limit customer disruption, but the extended Cincinnati ramp means supply constraints remain part of the business story through at least the first half of 2027.
Bottom line: This filing turns a known flooding event into a quantified, multi-quarter drag. The business is still generating cash and making operational progress, but the lower full-year guidance confirms that recovery will take longer and cost more than previously expected.
Read the original 8-K on SEC EDGAR ↗